Results 71 to 80 of about 339,257 (237)

Integrating APCS Score With Dual Biomarker Testing (FIT + mSEPT9) for Precision Risk Stratification and Predictive Modeling in High‐Risk Populations for Colorectal Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Asia‐Pacific Colorectal Screening (APCS) risk stratification was combined with quantitative fecal immunochemical test (FIT) and plasma methylated Septin9 to identify advanced colorectal neoplasia in a high‐risk cohort. The integrated model showed high apparent discrimination, while internal validation indicated a modest and uncertain incremental ...
WeiKang Ye   +6 more
wiley   +1 more source

PATHOPHYSIOLOGY OF VENOUS ULCERS

open access: yes, 2005
Why do patients develop venous ulcers? It is recognized that some form of abnormality of the venous system is a contributing factor but this does not explain the whole problem.

core   +1 more source

Chronic Iliac Vein Occlusion and Painful Nonhealing Ulcer Induced by High Venous Pressures from an Arteriovenous Malformation

open access: yesCase Reports in Radiology, 2011
Chronic femoral vein compression (May-Thurner Syndrome) is a known rare cause of deep venous thrombosis. Subsequent angiogenesis and the development of arteriovenous malformation (AVM) in the setting of chronic venous thrombosis is by itself a rare and ...
Daniel P. Link, Phillip J. Granchi
doaj   +1 more source

Design, Control, and Clinical Applications of Magnetic Actuation Systems: Challenges and Opportunities

open access: yesAdvanced Intelligent Systems, Volume 7, Issue 3, March 2025.
This review aims to provide a broad understanding for interdisciplinary researchers in engineering and clinical applications. It addresses the development and control of magnetic actuation systems (MASs) in clinical surgeries and their revolutionary effects in multiple clinical applications.
Yingxin Huo   +3 more
wiley   +1 more source

Effectiveness Of 2% And 4% Papain Gels In The Healing Of Venous Ulcers

open access: yesRevista da Escola de Enfermagem da USP
OBJECTIVE To analyze the effectiveness of 2% and 4% papain gels in tissue repair of venous ulcers. METHOD Quasi-experimental study with consecutive sample of 16 patients with 30 venous ulcers treated at the outpatient clinic of a teaching hospital, from ...
Andréa Pinto Leite Ribeiro   +5 more
doaj   +1 more source

Translational Macrophage Mechano‐Immunotherapy for Next‐Generation Implantable Biomaterials

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review explores how macrophage mechanosensing drives inflammation, fibrosis and foreign body responses to implanted biomaterials. It examines emerging pharmacological strategies to modulate mechanotransduction, alongside biomaterial platforms for localised drug delivery, clinical translation, regulatory considerations and standardised testing ...
Xueying Xu, Ian L. Chin, Richard P. Tan
wiley   +1 more source

Therapie chronischer Wunden mit wassergefiltertem Infrarot A (wIRA) [PDF]

open access: yes, 2008
The central portion of chronic wounds is often hypoxic and relatively hypothermic, representing a deficient energy supply of the tissue, which impedes wound healing or even makes it impossible.
Mercer, James B.   +11 more
core   +1 more source

Inframalleolar venous ulcers heal with Unna boot therapy

open access: yesJournal of Vascular Surgery: Venous and Lymphatic Disorders
Background: This study highlights the presentation of inframalleolar ulcers in venous disease, their wound healing factors, recurrence rate, and response to Unna boot treatment with adjunct endovenous and/or iliac vein stenting treatments.
Camille L. Karren, MS   +5 more
doaj   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

open access: yesThe Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy